Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/27/2026 14:55 PST] Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), Down By 100% ($0.48) From $0.48 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [02/10/2026 07:26 PST] ANEB Expected to Trade Down After Bearish Patterns Develop
• [01/06/2026 07:31 PST] ANEB Expected to Trade Up After Bullish Patterns Develop
• [01/05/2026 07:12 PST] ANEB Expected to Trade Up After Bullish Patterns Develop